Oncocyte corporation announces $10.2 million private placement of securities priced at-the-market under nasdaq rules

Company obtains participation from new and existing investors, including strategic partner bio-rad laboratories irvine, calif., oct. 02, 2024 – oncocyte corporation (nasdaq: ocx) (“oncocyte” or the “company”), a diagnostics technology company, today announced that it has entered into a securities purchase agreement (the “purchase agreement”) with new and existing investors, including bio-rad laboratories, inc.
NDAQ Ratings Summary
NDAQ Quant Ranking